Brad Nutter, chairman of Haemonetics’ board of directors, said, “We appreciate Rich’s leadership and guidance during his four-year tenure with Haemonetics. His breadth of experience in healthcare has been a strong complement to the Board, particularly as we’ve made key strategic decisions and transformed the Company from a niche medical device company to the global leader in blood management solutions for our customers.”
Meelia said, “During the past four years, Haemonetics made remarkable progress in transitioning into a higher growth profile company and is well positioned to deliver on its strategic and operational goals. I am proud of my association with the Company, its employees and my colleagues on the Board. There is an exciting future in store for this business.”
